SAB Biotherapeutics continues to seek engagement with partners and collaborators interested in using the DiversitAb™ Platform to produce unique, fully human antibodies against any antigens, including those that may have failed development in other antibody production systems. SAB's technology has been shown to produce antibodies, even where other technologies have failed.
The company is interested in projects including therapeutics for infectious disease, oncology, inflammation and autoimmunity as well as other potential fields. SAB's technology is suitable for recombinant antibody production (monoclonal/oligoclonal) as well as plasma derived polyclonal antibodies.
Please contact us at: email@example.com or call 605/679.6980.